2018 Cannabis Clinical Trials DEA 
NORML
JANUARY 17, 2019
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. A similar version of this bill was passed in the House Judiciary Committee in 2018 yet was not taken up by the full chamber.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Though, Oregon is actively in the process of establishing a model for psilocybin that would be like the state’s current medical cannabis system. Schedule I.
Canna Law Blog
JANUARY 3, 2023
Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”). 2018 Farm Bill. The 2018 Farm Bill didn’t regulate CBD though. States do their own thing.
Cannabis Law Report
JULY 9, 2021
Beginning in 2018, the FDA has started to grant special designations to study the medicinal use of psilocybin via Breakthrough Therapy status. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.
MedicalJane
JUNE 29, 2018
None of the approved drugs contain, or are derived from, the whole cannabis plant. On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). a Canada-based medical cannabis firm. “It rapidly destigmatizes what cannabis can do.” branch of Aphria, Inc.,
Cannabis Law Report
MARCH 2, 2020
The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. In 2018, the U.S. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment).
Expert insights. Personalized for you.
234 
Let's personalize your content